documents: FDA-2020-N-2252-0007

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2020-N-2252-0007 FDA FDA-2020-N-2252 Final Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments Notice Request for Comments 2022-02-24T05:00:00Z 2022 2 2022-02-24T05:00:00Z 2022-05-24T03:59:59Z 2022-05-24T01:01:00Z 2022-03926 0 0 0900006484f9f5b5

Links from other tables